Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Nature Medicine 13, 1144-1145 (1 October 2007) | doi:10.1038/nm1007-1144;
Where lies the blame for resistance|[mdash]|tumor or host?
Abstract
Targeted cancer therapy, as showcased by the Abelson murine leukemia viral oncogene homolog-1 (ABL) kinase inhibitor imatinib in the treatment of chronic myeloid leukemia (CML), has captivated the attention of the cancer world. Because they specifically attack the molecular underpinnings of a tumor, such as an oncogenic mutant kinase, these targeted drugs promise remarkable efficacy with minimal toxicity.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).